Total trials
319
Active
59
Phase 3
32
Total enrollment
65,362
Pipeline matrix
Showing 25 of 25 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| Escitalopram | — | — | — | — | 5 | ||
| Duloxetine | — | — | — | — | 4 | ||
| Exparel | — | — | — | — | — | 2 | |
| sertraline | — | — | — | — | — | 1 | |
| Bupivacain | — | — | — | — | — | 1 | |
| Sirolimus | — | — | 7 | ||||
| Conestat Alfa | — | — | — | — | — | 1 | |
| N-acetylcysteine | — | — | — | — | — | 1 | |
| Capecitabine | — | — | — | — | — | 1 | |
| Mitomycin c | — | — | — | — | — | 1 | |
| Pembrolizumab | — | — | — | — | — | 2 | |
| Gemcitabine | — | — | — | — | 3 | ||
| AM3101 | — | — | — | — | — | 1 | |
| Saline Placebo | — | — | — | — | — | 1 | |
| Treatment Algorithm | — | — | — | — | — | 1 | |
| Folfirinox | — | — | — | — | — | 1 | |
| Minocycline | — | — | — | — | — | 1 | |
| Letrozole | — | — | — | — | 2 | ||
| Pendulum Glucose Control | — | — | — | — | — | 1 | |
| Temozolomide | — | — | — | — | — | 1 | |
| C-peptide | — | — | — | — | — | 1 | |
| Everolimus | — | — | — | 3 | |||
| Bevacizumab | — | — | — | — | 2 | ||
| Lumason | — | — | — | — | — | 1 | |
| chemotherapy | — | — | — | — | — | 1 |
Next readouts
- 2025-06-03
- 2025-06-13
- 2025-06-30
- 2025-07
- 2025-07-30
- 2025-07-31
- 2025-12
- 2026-06-29
- 2026-06-30
- 2026-08-01
Top conditions
- Stroke18
- Sarcoidosis13
- Bipolar Disorder12
- Traumatic Brain Injury8
- Depression7
- Anxiety6
- Coronary Artery Disease5
- Lymphangioleiomyomatosis5
Frequently asked questions about University of Cincinnati
- How many clinical trials does University of Cincinnati have on ClinicalTrials.gov?
- University of Cincinnati is listed as the lead sponsor on 319 clinical trials in ClinicalTrials.gov, 59 of which are currently active (recruiting, enrolling, or ongoing).
- How many of University of Cincinnati's trials are in Phase 3?
- 32 of University of Cincinnati's trials are in Phase 3, spread across 25 active drug programs.
- What therapeutic areas does University of Cincinnati focus on?
- University of Cincinnati's most-studied conditions on ClinicalTrials.gov are Stroke, Sarcoidosis, Bipolar Disorder, Traumatic Brain Injury, Depression.
- When are University of Cincinnati's next clinical trial readouts?
- University of Cincinnati has 10 upcoming primary-completion readouts tracked here; the soonest is “Trial Combining Pembrolizumab and Cesium 131 Brachytherapy With Salvage Surgery in HNSCC”, expected around 2025-06-03.